Searching for the next breakthrough is not a one-person job. In fact, it’s not a one-company job either. Discovering life-changing medicines requires a diverse team of dedicated experts from different places and with different viewpoints and approaches. Collaboration, even if the term seems overused, is what allows us to discover medicines more efficiently and successfully. Plus, as scientists who are passionate about what we do, there’s nothing we love more than to discuss, debate and examine our research as a way to improve our approach to discovering new medicines.
So how are we teaming up to deliver better medicines faster at Lilly? Expanded connections are key and have been our focus in 2015.
- Expand R&D footprint: Building on our recent center opening in Cambridge, Massachusetts, and expansion in San Diego, California, our latest expansion at the Alexandria Center for Life Science in New York City provides us with the opportunity to further strengthen our focus in immuno-oncology, quantitative biology and discovery automation. This will not only grow our bench of scientists, but help pave the way for collaboration with leading academic, health care and industry colleagues.
- Seek external innovation: We want to attract novel ideas about how to use better disease understanding to discover and develop new medicines in our prioritized therapeutic areas using several approaches. This can evolve into close collaborations between academic and Lilly scientists. What's more, through our Open Innovation Drug Discovery (OIDD) platform, external investigators have access to Lilly’s tools and expertise so they can design and submit new molecules, ultimately furthering the early drug discovery process.
- Strengthen internal talent: Because finding a cure is no easy task, we understand the importance of bringing together all facets of the process. This includes taking a collaborative approach internally, such as building integrated teams of biologists and chemists, to work toward solving problems and discovering life-changing medicines.
At the end of the day, we believe it is through connections—internal and external collaboration—that we will ultimately deliver valuable medicines to patients faster.